CY1106303T1 - Συνδυασμοι οι οποιοι πepιλαμβανουν αναστολεις πεπτιδυλικης διπεπτιδασης-iv και αντιδιαβητικους παραγοντες - Google Patents
Συνδυασμοι οι οποιοι πepιλαμβανουν αναστολεις πεπτιδυλικης διπεπτιδασης-iv και αντιδιαβητικους παραγοντεςInfo
- Publication number
- CY1106303T1 CY1106303T1 CY20061101859T CY061101859T CY1106303T1 CY 1106303 T1 CY1106303 T1 CY 1106303T1 CY 20061101859 T CY20061101859 T CY 20061101859T CY 061101859 T CY061101859 T CY 061101859T CY 1106303 T1 CY1106303 T1 CY 1106303T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- glucose
- fructose
- insulin
- phosphatase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 8
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 229940125708 antidiabetic agent Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000010444 Acidosis Diseases 0.000 abstract 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 108030006877 Dipeptidyl-dipeptidases Proteins 0.000 abstract 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 abstract 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000007976 Ketosis Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010027417 Metabolic acidosis Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000030136 gastric emptying Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000009229 glucose formation Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 230000004155 insulin signaling pathway Effects 0.000 abstract 1
- 230000004140 ketosis Effects 0.000 abstract 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Η παρούσα εφεύρεση σχετίζεται με έναν συνδυασμό ο οποίος περιλαμβάνει έναν αναστολέα πεπτιδυλικής διπεπτιδάσης - IV και τουλάχιστον μια ακόμη αντιδιαβητική ένωση, η οποία έχει επιλεγεί κατά προτίμηση από την ομάδα εκείνη που αποτελείται από ρυθμιστές ινσουλίνης πορείας σήματος, όπως είναι για παράδειγμα οι αναστολείς της πρωτεϊνικής φωσφατάσης τυροσίνης ( protein tyrosine phosphatases - PTPases ), μιμητικές ενώσεις μη μικρών μορίων και αναστολείς αμιδοτρανσφεράσης γλουταμινο - φρουκτόζη - 6 - φωσφατάσης ( glutamine -fructose - 6 - phosphate amidotransferase - GFAT ), ενώσεις οι οποίες επηρεάζουν μια δυσλειτουργική παραγωγή ηπατικής γλυκόζης, όπως είναι για παράδειγμα οι αναστολείς γλυκόζη - 6 - φωσφατάσης ( glucose - 6 - phosphatase - G6Pase ), οι αναστολείς φρουκτόζη - 1, 6 - δισφωσφατάση ( fructose - 1, 6 - BPase ), οι αναστολείς φωσφορυλάσης γλυκογόνου ( glycogen phosphorylase - GP ), οι ανταγωνιστές υποδοχής γλυκαγόνου και οι αναστολείς φωσφοενολπυρουβικής καρβοξυκινάσης ( phosphoenolpyruvate carvoxykinase - PEPCK ), οι αναστολείς πυρουβικής διϋδρογονάσης κινάσης ( pyruvate dehydrogenase kinase - PDHK ), ενισχυτικά ευαισθησίας στην ινσουλίνη, ενισχυτικά έκκρισης ινσουλίνης, αναστολείς α - γλουκοσιδάσης, αναστολείς γαστρικής κένωσης, ινσουλίνη, και ανδρενεργικούς α2 ανταγωνιστές, για ταυτόχρονη, ξεχωριστή ή διαδοχική χρήση στην πρόληψη, καθυστέρηση της προόδου ή θεραπεία των συνθηκών που μεσολαβούν από την πεπτιδυλική διπεπτιδάση - IV ( dipeptidylpeptidase - IV ( DPP - IV ) ), και συγκεκριμένα του διαβήτη, και ακόμη πιο συγκεκριμένα του σακχαρώδους διαβήτη τύπου 2, συνθηκών διαταραγμένης ανοχής στη γλυκόζη ( impaired glucose tolerance - IGT ), συνθηκών διαταραγμένου σακχάρου νηστείας ( impaired fasting plasma glucose - IFG ), μεταβολική οξέωση, κέτωση, αρθρίτιδα, παχυσαρκία και οστεοπόρωση. Επίσης σχετίζεται με την χρήση αυτού του είδους συνδυασμού για την αισθητική θεραπεία ενός θηλαστικού προκειμένου να έχει ως αποτέλεσμα μια αισθητικά ωφέλιμη απώλεια σωματικού βάρους.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48923400A | 2000-01-21 | 2000-01-21 | |
US61926200A | 2000-07-19 | 2000-07-19 | |
PCT/EP2001/000590 WO2001052825A2 (en) | 2000-01-21 | 2001-01-19 | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106303T1 true CY1106303T1 (el) | 2011-10-12 |
Family
ID=27049636
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101859T CY1106303T1 (el) | 2000-01-21 | 2006-12-29 | Συνδυασμοι οι οποιοι πepιλαμβανουν αναστολεις πεπτιδυλικης διπεπτιδασης-iv και αντιδιαβητικους παραγοντες |
CY20081100459T CY1107423T1 (el) | 2000-01-21 | 2008-04-24 | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες |
CY200800010C CY2008010I2 (el) | 2000-01-21 | 2008-05-12 | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες |
CY20131100877T CY1114466T1 (el) | 2000-01-21 | 2013-10-09 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-διπεπτιδασης-ιv και αντιδιαβητικους παραγοντες |
CY20131100996T CY1114593T1 (el) | 2000-01-21 | 2013-11-08 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-διπεπτιδασης-iv kai αντιδιαβητικους παραγοντες |
CY20141100633T CY1115449T1 (el) | 2000-01-21 | 2014-08-08 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-πεπτιδασης-iv και αντιδιαβητικους παραγοντες |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100459T CY1107423T1 (el) | 2000-01-21 | 2008-04-24 | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες |
CY200800010C CY2008010I2 (el) | 2000-01-21 | 2008-05-12 | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες |
CY20131100877T CY1114466T1 (el) | 2000-01-21 | 2013-10-09 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-διπεπτιδασης-ιv και αντιδιαβητικους παραγοντες |
CY20131100996T CY1114593T1 (el) | 2000-01-21 | 2013-11-08 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-διπεπτιδασης-iv kai αντιδιαβητικους παραγοντες |
CY20141100633T CY1115449T1 (el) | 2000-01-21 | 2014-08-08 | Συνδυασμοι οι οποιοι περιλαμβανουν αναστολεις διπεπτιδυλ-πεπτιδασης-iv και αντιδιαβητικους παραγοντες |
Country Status (18)
Country | Link |
---|---|
US (1) | US20030139434A1 (el) |
EP (5) | EP1741445B1 (el) |
JP (7) | JP2003520226A (el) |
CN (3) | CN1977842A (el) |
AT (2) | ATE346613T1 (el) |
AU (1) | AU2001237321A1 (el) |
BR (1) | BRPI0107715B8 (el) |
CA (2) | CA2673615C (el) |
CY (6) | CY1106303T1 (el) |
DE (3) | DE60132723T2 (el) |
DK (5) | DK1743655T3 (el) |
ES (5) | ES2436610T3 (el) |
FR (1) | FR08C0017I2 (el) |
HK (4) | HK1102405A1 (el) |
LU (1) | LU91436I2 (el) |
NL (1) | NL300346I1 (el) |
PT (5) | PT1741447E (el) |
WO (1) | WO2001052825A2 (el) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
PT1112275E (pt) | 1998-09-09 | 2003-12-31 | Metabasis Therapeutics Inc | Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase |
US6852760B1 (en) * | 1998-09-17 | 2005-02-08 | Akesis Pharmaceuticals, Inc. | Compositions and methods for treatment for glucose metabolism disorders |
DE60132723T2 (de) * | 2000-01-21 | 2009-01-29 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
PL357251A1 (en) | 2000-03-08 | 2004-07-26 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-bisphosphatase inhibitors |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
PL365779A1 (en) * | 2000-07-06 | 2005-01-10 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
CZ20031125A3 (cs) * | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Nové sloučeniny |
ES2296962T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Pirrolidinas como inhibidores de dipeptidil peptidasa. |
EP1399433B1 (en) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
ATE455759T1 (de) | 2001-06-27 | 2010-02-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidylpeptidasehemmer |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
US7524885B2 (en) * | 2002-04-01 | 2009-04-28 | The Governors Of The University Of Alberta | Compounds that stimulate glucose utilization and methods of use |
GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
EP3424926A1 (de) * | 2002-08-21 | 2019-01-09 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1534314B1 (en) * | 2002-09-04 | 2014-10-22 | DSM IP Assets B.V. | A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
EP1557165A4 (en) * | 2002-09-26 | 2008-12-03 | Eisai R&D Man Co Ltd | COMBINED MEDICINE |
US20060111428A1 (en) * | 2002-12-10 | 2006-05-25 | Pei-Ran Wang | Combination of an dpp-iv inhibitor and a ppar-alpha compound |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
KR20060105431A (ko) * | 2003-06-27 | 2006-10-11 | 닥터 레디스 리서치 파운데이션 | 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물 |
FR2858556B1 (fr) * | 2003-08-06 | 2006-03-10 | Galenix Innovations | Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1506967B1 (en) | 2003-08-13 | 2007-11-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MXPA06002127A (es) * | 2003-09-02 | 2006-05-31 | Prosidion Ltd | Terapia combinada para control glucemico. |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
CA2545641A1 (en) | 2003-11-17 | 2005-06-02 | Novartis Ag | Use of organic compounds |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
LT3366283T (lt) | 2004-01-20 | 2021-12-10 | Novartis Ag | Tiesioginio presavimo formulė ir procesas |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
JP2007261945A (ja) * | 2004-04-07 | 2007-10-11 | Taisho Pharmaceut Co Ltd | チアゾール誘導体 |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7935723B2 (en) | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7842707B2 (en) | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
WO2006022428A1 (ja) * | 2004-08-26 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
AU2005299808B2 (en) * | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN101332303B (zh) * | 2005-01-10 | 2012-09-26 | 艾尼纳制药公司 | 用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法 |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MX2007012951A (es) * | 2005-03-25 | 2008-01-11 | Glaxo Group Ltd | Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona. |
UY29440A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
JP2008115080A (ja) * | 2005-04-22 | 2008-05-22 | Taisho Pharmaceutical Co Ltd | 併用医薬 |
US7553861B2 (en) | 2005-04-22 | 2009-06-30 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
KR101438234B1 (ko) * | 2005-06-03 | 2014-09-04 | 미쓰비시 타나베 파마 코퍼레이션 | 의약의 병용 및 그 용도 |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
EP1898931B1 (en) * | 2005-07-07 | 2014-12-31 | Postech Foundation | Glucose uptake modulator and method for treating diabetes or diabetic complications |
EP1904058A2 (en) * | 2005-07-12 | 2008-04-02 | Novartis AG | Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
WO2007035665A1 (en) * | 2005-09-20 | 2007-03-29 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
WO2007041368A2 (en) * | 2005-09-30 | 2007-04-12 | Novartis Ag | Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection |
CA2625150A1 (en) * | 2005-10-07 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Combined use of dpp-iv inhibitors and gastrin compounds |
CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
GEP20105033B (en) * | 2005-12-28 | 2010-06-25 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1971862B1 (en) | 2006-04-11 | 2010-11-10 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
GEP20125701B (en) * | 2006-09-13 | 2012-12-10 | Takeda Pharmaceuticals Co | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
JP2010043002A (ja) * | 2006-11-27 | 2010-02-25 | Ajinomoto Co Inc | 糖尿病治療剤 |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
MY147596A (en) | 2007-02-01 | 2012-12-31 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and pioglitazone |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
EP2275108B1 (en) * | 2008-05-14 | 2014-07-09 | Sanwa Kagaku Kenkyusho Co., Ltd | Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CA2744697C (en) | 2008-11-26 | 2016-06-21 | Satiogen Pharmaceuticals, Inc. | Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes |
CN102316872B (zh) | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
US8445538B2 (en) * | 2008-12-19 | 2013-05-21 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
NZ594487A (en) | 2009-02-13 | 2013-11-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
ES2812537T3 (es) | 2009-10-21 | 2021-03-17 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
CA2793835C (en) | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
EP2556056A1 (en) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013063512A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
BR112017019170A2 (pt) | 2015-03-09 | 2018-07-10 | Intekrin Therapeutics, Inc. | métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
JP2022548214A (ja) | 2019-09-17 | 2022-11-17 | ノバルティス アーゲー | ビルダグリプチンとメトホルミンとの組み合わせ療法 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US489795A (en) | 1893-01-10 | Steadying device for portable engines | ||
US988496A (en) | 1910-09-19 | 1911-04-04 | Henry Obermann | Ventilator. |
US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4342771A (en) * | 1981-01-02 | 1982-08-03 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US5216167A (en) * | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US4703052A (en) | 1985-05-21 | 1987-10-27 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
EP0306228B1 (en) | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
CA2067216A1 (en) | 1989-10-25 | 1991-04-26 | Cary Alan Weinberger | Receptor infection assay |
US4997948A (en) | 1989-10-27 | 1991-03-05 | American Home Products | 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
EP0752477A3 (en) | 1990-01-16 | 1997-05-14 | Baylor College Medicine | Expression vectors for the production of steroid receptors, chimeras of these receptors, screening tests for these receptors and clinical tests using the synthesized receptors and their vectors |
CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
DK0552202T3 (da) | 1990-09-21 | 1996-06-03 | Salk Inst For Biological Studi | Fremgangsmåder medieret af det protoonkogene proteinkompleks AP-1 |
DK0526171T3 (da) | 1991-07-30 | 1997-08-25 | Ajinomoto Kk | Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf |
US5866563A (en) | 1991-09-30 | 1999-02-02 | The University Of British Columbia | Vanadium compositions |
WO1993011235A1 (en) | 1991-12-06 | 1993-06-10 | The Salk Institute For Biological Studies | Multimeric forms of members of the steroid/thyroid superfamily of receptors |
CA2123223C (en) | 1991-12-18 | 2001-10-09 | Ronald M. Evans | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
CA2133587C (en) | 1992-04-22 | 2008-11-18 | Marcus F. Boehm | Compounds having selectivity for retinoid x receptors |
DE69334150T2 (de) | 1992-05-14 | 2008-03-13 | Baylor College Of Medicine, Houston | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
US5466861A (en) | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
WO1994015901A1 (en) | 1993-01-11 | 1994-07-21 | Ligand Pharmaceuticals Inc. | Compounds having selectivity for retinoid x receptors |
EP0678086B1 (en) | 1993-01-11 | 1999-12-08 | Ligand Pharmaceuticals, Inc. | Compounds having selectivity for retinoid x receptors |
CA2153236A1 (en) | 1993-01-11 | 1995-02-09 | Marcus F. Boehm | Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors |
US5399586A (en) | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
CA2160135A1 (en) | 1993-04-07 | 1994-10-13 | Donald P. Mcdonnell | Method for screening for receptor agonists |
US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
WO1995018380A1 (en) | 1993-12-30 | 1995-07-06 | The Salk Institute For Biological Studies | Novel uses for gal4-receptor constructs |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
DE4416433A1 (de) | 1994-05-10 | 1995-11-16 | Hoechst Ag | Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten |
US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
CZ288526B6 (cs) | 1994-08-10 | 2001-07-11 | F. Hoffmann-La Roche Ag | Deriváty tetrahydronaftalenu nebo indanu, farmaceutické přípravky na jejich bázi a meziprodukty pro přípravu těchto derivátů |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
ATE187157T1 (de) | 1994-12-30 | 1999-12-15 | Ligand Pharm Inc | Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung |
PT800503E (pt) | 1994-12-30 | 2000-11-30 | Ligand Pharm Inc | Novos compostos retinoides trienoicos e metodos |
DE69522718T2 (de) | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren |
EP0832065B1 (en) | 1995-06-06 | 2001-10-10 | Pfizer Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
JPH11514651A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 置換ピリジルピロール、前記化合物を含む組成物及び使用方法 |
WO1997031901A1 (en) | 1996-02-29 | 1997-09-04 | Mikael Bols | Hydroxyhexahydropyridazines |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
EP1019043A4 (en) | 1996-05-07 | 2003-07-30 | Univ Pennsylvania | GLYCOGENE SYNTHETASE KINASE-3 INHIBITORS AND METHODS OF IDENTIFYING AND USING THOSE INHIBITORS |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
JP4010377B2 (ja) | 1996-09-06 | 2007-11-21 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
CA2271963A1 (en) | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
AU730295B2 (en) | 1996-11-20 | 2001-03-01 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
US5880139A (en) | 1996-11-20 | 1999-03-09 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
AU726311B2 (en) | 1996-11-20 | 2000-11-02 | Merck & Co., Inc. | Triaryl substituted imidazoles and methods of use |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
IL131130A0 (en) | 1997-01-28 | 2001-01-28 | Merck & Co Inc | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
DK0970095T3 (da) | 1997-03-07 | 2004-03-08 | Metabasis Therapeutics Inc | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase |
JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | 4,5,6,7−テトラヒドロ−チエノ[3,2−c]ピリジン誘導体類、それらの製造方法及び使用 |
WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US6169087B1 (en) | 1997-09-23 | 2001-01-02 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
WO1999029672A1 (en) | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | SELECTIVE β3 ADRENERGIC AGONISTS |
WO1999038501A2 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
AU2610299A (en) | 1998-02-05 | 1999-08-23 | Novo Nordisk A/S | Hydrazone derivatives |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
AU2713699A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
JP2002506073A (ja) | 1998-03-12 | 2002-02-26 | ノボ ノルディスク アクティーゼルスカブ | プロテイン・チロシン・ホスファターゼ(PTPases)のモジュレーター |
AU2713799A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
HUP0102612A2 (hu) | 1998-03-12 | 2001-11-28 | Novo Nordisk A/S | Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények |
WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
AU3087099A (en) | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
ATE286032T1 (de) | 1998-04-23 | 2005-01-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
CN1308625A (zh) | 1998-05-12 | 2001-08-15 | 美国家用产品公司 | 萘并[2,3-b]杂芳-4-基衍生物 |
US6001867A (en) | 1998-05-12 | 1999-12-14 | American Home Products Corporation | 1-aryl-dibenzothiophenes |
EP1077967B1 (en) | 1998-05-12 | 2002-12-04 | Wyeth | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US6057316A (en) | 1998-05-12 | 2000-05-02 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
WO2000014090A1 (en) | 1998-09-02 | 2000-03-16 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives |
PT1112275E (pt) | 1998-09-09 | 2003-12-31 | Metabasis Therapeutics Inc | Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase |
EP1119548B1 (en) | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3) |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6030837A (en) | 1999-08-03 | 2000-02-29 | Isis Pharmaceuticals Inc. | Antisense inhibition of PEPCK-mitochondrial expression |
DE60132723T2 (de) * | 2000-01-21 | 2009-01-29 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
TW200303742A (en) † | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2001
- 2001-01-19 DE DE60132723T patent/DE60132723T2/de not_active Expired - Lifetime
- 2001-01-19 ES ES06121896.2T patent/ES2436610T3/es not_active Expired - Lifetime
- 2001-01-19 EP EP06121894.7A patent/EP1741445B1/en not_active Expired - Lifetime
- 2001-01-19 CN CNA2006101699199A patent/CN1977842A/zh active Pending
- 2001-01-19 ES ES06121895T patent/ES2301142T3/es not_active Expired - Lifetime
- 2001-01-19 EP EP01909661A patent/EP1248604B2/en not_active Expired - Lifetime
- 2001-01-19 DK DK06121898.8T patent/DK1743655T3/da active
- 2001-01-19 PT PT61218962T patent/PT1741447E/pt unknown
- 2001-01-19 DK DK06121894.7T patent/DK1741445T3/da active
- 2001-01-19 ES ES06121894T patent/ES2433476T3/es not_active Expired - Lifetime
- 2001-01-19 PT PT61218947T patent/PT1741445E/pt unknown
- 2001-01-19 US US10/181,169 patent/US20030139434A1/en not_active Abandoned
- 2001-01-19 EP EP06121896.2A patent/EP1741447B1/en not_active Expired - Lifetime
- 2001-01-19 DE DE60124861T patent/DE60124861T2/de not_active Expired - Lifetime
- 2001-01-19 ES ES06121898.8T patent/ES2487897T3/es not_active Expired - Lifetime
- 2001-01-19 AU AU2001237321A patent/AU2001237321A1/en not_active Abandoned
- 2001-01-19 CN CN01803953A patent/CN1400908A/zh active Pending
- 2001-01-19 JP JP2001552873A patent/JP2003520226A/ja active Pending
- 2001-01-19 BR BRPI0107715A patent/BRPI0107715B8/pt not_active IP Right Cessation
- 2001-01-19 WO PCT/EP2001/000590 patent/WO2001052825A2/en active IP Right Grant
- 2001-01-19 DK DK06121896.2T patent/DK1741447T3/da active
- 2001-01-19 CA CA2673615A patent/CA2673615C/en not_active Expired - Lifetime
- 2001-01-19 PT PT01909661T patent/PT1248604E/pt unknown
- 2001-01-19 AT AT01909661T patent/ATE346613T1/de active
- 2001-01-19 DK DK01909661.9T patent/DK1248604T4/da active
- 2001-01-19 PT PT06121895T patent/PT1741446E/pt unknown
- 2001-01-19 EP EP06121895A patent/EP1741446B1/en not_active Expired - Lifetime
- 2001-01-19 CA CA002397554A patent/CA2397554C/en not_active Expired - Lifetime
- 2001-01-19 EP EP06121898.8A patent/EP1743655B1/en not_active Expired - Lifetime
- 2001-01-19 PT PT61218988T patent/PT1743655E/pt unknown
- 2001-01-19 AT AT06121895T patent/ATE385421T1/de active
- 2001-01-19 DK DK06121895T patent/DK1741446T3/da active
- 2001-01-19 DE DE122008000018C patent/DE122008000018I1/de active Pending
- 2001-01-19 CN CN2011102233943A patent/CN102327614A/zh active Pending
- 2001-01-19 ES ES01909661T patent/ES2275654T5/es not_active Expired - Lifetime
-
2006
- 2006-07-10 JP JP2006189416A patent/JP2006273873A/ja active Pending
- 2006-12-29 CY CY20061101859T patent/CY1106303T1/el unknown
-
2007
- 2007-06-27 HK HK07106895A patent/HK1102405A1/xx unknown
- 2007-06-27 HK HK07106890.1A patent/HK1102422A1/xx not_active IP Right Cessation
- 2007-06-27 HK HK07106894.7A patent/HK1102424A1/xx unknown
- 2007-07-16 HK HK07107617.1A patent/HK1108359A1/xx not_active IP Right Cessation
-
2008
- 2008-04-24 CY CY20081100459T patent/CY1107423T1/el unknown
- 2008-05-09 LU LU91436C patent/LU91436I2/fr unknown
- 2008-05-12 CY CY200800010C patent/CY2008010I2/el unknown
- 2008-05-14 FR FR08C0017C patent/FR08C0017I2/fr active Active
- 2008-05-14 NL NL300346C patent/NL300346I1/nl unknown
-
2011
- 2011-03-02 JP JP2011045331A patent/JP5835910B2/ja not_active Expired - Lifetime
- 2011-03-30 JP JP2011076253A patent/JP5824224B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-09 CY CY20131100877T patent/CY1114466T1/el unknown
- 2013-11-08 CY CY20131100996T patent/CY1114593T1/el unknown
-
2014
- 2014-02-06 JP JP2014020963A patent/JP6095589B2/ja not_active Expired - Lifetime
- 2014-08-08 CY CY20141100633T patent/CY1115449T1/el unknown
-
2015
- 2015-07-31 JP JP2015151372A patent/JP6104331B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-19 JP JP2017007638A patent/JP6374995B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106303T1 (el) | Συνδυασμοι οι οποιοι πepιλαμβανουν αναστολεις πεπτιδυλικης διπεπτιδασης-iv και αντιδιαβητικους παραγοντες | |
US8222291B2 (en) | Small molecule apoptosis promoters | |
BR0212477A (pt) | 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças | |
MXPA05000896A (es) | Derivados de 2-ciano-4-fluoropirrolidina o su sal. | |
KR20130120517A (ko) | 암을 치료하기 위한 hdac 억제제로서 4-아미노-n-하이드록시-벤즈아미드 | |
PT1137413E (pt) | Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao | |
WO2006084757A3 (en) | Combination of ca/mg salt of valsartan with an antidiabetic agent |